Page updated Oct 6, 2026 · using data updated on Nov 12, 2026
Trispecific antibodies — Platform Heatmap
Antibodies that bind three different targets at once, across cancer and immunology. None is approved yet; a handful are in Phase 3.
32 active programs
62 indications
74 trials
3 at Phase 3 or later
27 sponsors
Targets: CD3 · BCMA · GPRC5D · CD20 · CD19 · VEGF
Beta 20 programs of 32 20 indications of 62 46 programs mapped curated roster · no per-cell AI classification ⏰ 7 due ≤6 mo click any cell → asset tearsheet
At a glance
20 programs in this class span 20 indications (46 drug–indication pairs mapped). The most contested indication is Multiple Myeloma (18 programs).
Forward catalysts next 18 months⏰ 7 due ≤6 mo
Nearest first. ⚖ Confirmed FDA PDUFA dates (curated calendar, primary sources) and 📅 estimated readouts (ClinicalTrials.gov
primaryCompletionDate — a timing proxy, not a confirmed action date). Red = due within 6 months.Drug × Indication
Each cell = this program’s trials in that indication. Click for details. · showing top 20 of 32 programs × top 20 of 62 indications by program count — long tail omitted for width, not a data cap.
Select & Focus Pro → 🔒 Transpose, filtering, selection & export are Pro (search & sort are free) — start a free trial, or try them free on our showcase →
Multiple Myeloma | Non-Hodgkin Lymphoma | Systemic Lupus Erythematosus | Atopic Dermatitis | Rheumatoid Arthritis | B-Cell Chronic Lymphocytic Leukem… | Precursor Cell Lymphoblastic Leuk… | Chronic Obstructive Pulmonary Dis… | Immunoglobulin Light-chain Amyloi… | Myositis | Solid Tumor | Advanced Solid Tumor Cancer | Cancer | Dermatitis | Eczematous Skin Diseases | Asthma | Amyloidosis | Smoldering Multiple Myeloma | Malignant Plasma Cell Neoplasms | Plasma Cell Neoplasms | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| tilrekimigPfizerIL-4 × IL-13 × TSLP | ||||||||||||||||||||
| AZD5492AstraZenecaCD20 × TCR × CD8 | ||||||||||||||||||||
| ramantamigJohnson & JohnsonBCMA × GPRC5D × CD3 | ||||||||||||||||||||
| GSK5926371GSKCD19 × CD20 × CD3 | ||||||||||||||||||||
| HC010HC BiopharmaPD-1 × CTLA-4 × VEGF | ||||||||||||||||||||
| PIT565NovartisCD19 × CD2 × CD3 | ||||||||||||||||||||
| QLS4131Qilu PharmaceuticalBCMA × GPRC5D × CD3 | ||||||||||||||||||||
| IBI3003Innovent BiologicsGPRC5D × BCMA × CD3 | ||||||||||||||||||||
| anafiltamigJohnson & JohnsonCD79b × CD20 × CD3 | ||||||||||||||||||||
| CC312CytoCaresCD19 × CD3 × CD28 | ||||||||||||||||||||
| galvokimigUCBIL-13 × IL-17A × IL-17F | ||||||||||||||||||||
| ISB 2001AbbVieBCMA × CD38 × CD3 | ||||||||||||||||||||
| DR30206Zhejiang Doer BiologicsVEGF × PD-L1 × TGF-beta | ||||||||||||||||||||
| TAVO412Tavotek BiotherapeuticsEGFR × c-MET × VEGF | ||||||||||||||||||||
| SIM0500Simcere ZaimingGPRC5D × BCMA × CD3 | ||||||||||||||||||||
| MBS314Beijing Mabworks BiotechGPRC5D × BCMA × CD3 | ||||||||||||||||||||
| JNJ-95566692Johnson & JohnsonCD79b × CD20 × CD3 | ||||||||||||||||||||
| KT501SanofiCD19 × BCMA × CD3 | ||||||||||||||||||||
| GTB-5550GT BiopharmaB7-H3 × CD16a × IL-15 rec… | ||||||||||||||||||||
| ompekimigPfizerIL-4 × IL-13 × IL-33 |
Beyond the grid Beta
What the matrix leaves out — rare mechanisms with only one player, small & emerging sponsors, and programs we haven’t classified yet.
White-space indications — a single asset 51 found
Indications where only ONE asset in this family competes — uncrowded ground for a new entrant.
⚡ first-in-class · 🌱 first-in-indication · 🆕 NME candidate · ✅ AI-classified + verified · ⚙️ AI-classified, unverified · first-in-class computed across 1 mapped landscape
Trispecific antibodies
32 active programs, most advanced first.
| Drug | Targets | Sponsor | Phase | Main indications | Trials |
|---|---|---|---|---|---|
| IBI3003 | GPRC5D × BCMA × CD3 | Innovent Biologics | Phase 3 | Multiple Myeloma | 4 |
| ramantamig | BCMA × GPRC5D × CD3 | Johnson & Johnson Janssen | Phase 3 | Multiple Myeloma · Amyloidosis · Smoldering Multiple Myeloma | 9 |
| tilrekimig | IL-4 × IL-13 × TSLP | Pfizer | Phase 3 | Atopic Dermatitis · Dermatitis · Eczematous Skin Diseases | 10 |
| CS2009 | PD-1 × VEGF-A × CTLA-4 | CStone Pharmaceuticals | Phase 2 | Advanced Solid Tumors | 1 |
| galvokimig Also on Immunology bispecifics | IL-13 × IL-17A × IL-17F | UCB | Phase 2 | Atopic Dermatitis · Chronic Obstructive Pulmonary Disease · Chronic Bronchitis | 5 |
| HC010 | PD-1 × CTLA-4 × VEGF | HC Biopharma | Phase 2 | Advanced Solid Tumor Cancer · NSCLC · Non-Small-Cell Lung Carcinoma | 4 |
| ompekimig | IL-4 × IL-13 × IL-33 | Pfizer | Phase 2 | Atopic Dermatitis | 3 |
| QLS4131 | BCMA × GPRC5D × CD3 | Qilu Pharmaceutical | Phase 2 (registered, not yet recruiting) | Malignant Plasma Cell Neoplasms · Immunoglobulin Light-chain Amyloidosis · Plasma Cell Neoplasms | 4 |
| AK150 | ILT2 (LILRB1) × ILT4 (LILRB2) × CSF1R | Akeso | Phase 1 | Advanced Malignant Solid Tumors | 1 |
| AN8025 | PD-L1 × CD28/CTLA-4 (via CD86 variant) × MHC class II (via LAG-3 variant) | Adlai Nortye | Phase 1 | Advanced Solid Tumor (Phase 1) | 1 |
| anafiltamig | CD79b × CD20 × CD3 | Johnson & Johnson Janssen | Phase 1 | Non-Hodgkin Lymphoma · B-Cell Chronic Lymphocytic Leukemia | 3 |
| AZD5492 Trispecific per literature | CD20 × TCR × CD8 | AstraZeneca | Phase 1 | B-Cell Leukemia · B-Cell Chronic Lymphocytic Leukemia · Mantle-Cell Lymphoma | 2 |
| CC312 | CD19 × CD3 × CD28 | CytoCares | Phase 1 | Systemic Lupus Erythematosus · Non-Hodgkin Lymphoma · Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| DR30206 Trispecific per literature | VEGF × PD-L1 × TGF-beta | Zhejiang Doer Biologics | Phase 1 | Gastrointestinal Neoplasms · Solid Tumor | 2 |
| EVOLVE104 Trispecific per literature | ULBP2/5/6 × CD3 × CD2 | EvolveImmune Therapeutics | Phase 1 | Urinary Bladder Neoplasms · Esophageal Squamous Cell Carcinoma · Anus Neoplasms | 1 |
| EXP011 | DLL3 × CD3 × CD137 (4-1BB) | Excalipoint Therapeutics | Phase 1 | small cell lung cancer · Neuroendocrine Tumors | 0 |
| GB268 | PD-1 × CTLA-4 × VEGF | Genor Biopharma | Phase 1 | Breast Neoplasms · Solid Tumor Cancer | 2 |
| GSK5926371 | CD19 × CD20 × CD3 | GSK | Phase 1 | Non-Hodgkin Lymphoma · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Systemic Lupus Erythematosus | 4 |
| GTB-3650 | CD16a × CD33 × IL-15 receptor (via IL-15) | GT Biopharma | Phase 1 | Acute Myeloid Leukemia · Myelodysplastic Syndromes | 1 |
| GTB-5550 | B7-H3 × CD16a × IL-15 receptor (via IL-15) | GT Biopharma | Phase 1 | Solid Tumor | 1 |
| HLX3902 | STEAP1 × CD3 × CD28 | Shanghai Henlius Biotech | Phase 1 | mCRPC or Advanced/Metastatic Solid Tumors | 1 |
| ISB 2001 | BCMA × CD38 × CD3 | AbbVie | Phase 1 | Multiple Myeloma | 2 |
| JNJ-95566692 | CD79b × CD20 × CD3 | Johnson & Johnson Janssen | Phase 1 | Non-Hodgkin Lymphoma | 1 |
| KT501 | CD19 × BCMA × CD3 | Sanofi worldwide exclusive license from Kali Therapeutics, 2026-03-23 | Phase 1 | Rheumatoid Arthritis | 1 |
| LBL-051 | BCMA × CD19 × CD3 | Oblenio Bio | Phase 1 | refractory autoimmune diseases | 0 |
| MBS314 | GPRC5D × BCMA × CD3 | Beijing Mabworks Biotech | Phase 1 | Multiple Myeloma | 1 |
| PIT565 | CD19 × CD2 × CD3 | Novartis | Phase 1 | B-Cell Lymphoma · Burkitt Lymphoma · Non-Hodgkin Lymphoma | 3 |
| QLS2313 | CD79b × CD20 × CD3 | Qilu Pharmaceutical | Phase 1 | Hematologic Neoplasms | 1 |
| SIM0500 | GPRC5D × BCMA × CD3 | Simcere Zaiming Jiangsu Simcere | Phase 1 | Multiple Myeloma | 1 |
| SOA101 | PD-L1 × HLA-G × CD3 | Shine-On Biomedical | Phase 1 | Solid Tumors | 1 |
| SYS6088 | PD-1 × CTLA-4 × VEGF | CSPC Megalith Biopharmaceutical | Phase 1 | Advanced/Metastatic Solid Tumors | 1 |
| TAVO412 Trispecific per literature | EGFR × c-MET × VEGF | Tavotek Biotherapeutics | Phase 1 | Cancer | 2 |
Discontinued
Programs whose sponsor stopped development since 2023, with the stated date and reason.
| Drug | Targets | Sponsor | Status |
|---|---|---|---|
| SAR442257 | CD38 × CD28 × CD3 | Sanofi | discontinued (2026-05, Ph1 terminated: limited clinical benefit in MM and NHL) |
| SAR443216 | HER2 × CD3 × CD28 | Sanofi | discontinued (2024-01, Ph1 terminated; no reason on CT.gov) |
| CC-96191 | CD33 × NKG2D × CD16a (via Fc) | Bristol Myers Squibb | discontinued (2025-04, Ph1 terminated: business objectives changed) |
| ingitamig | BCMA × NKG2D × CD16a (via Fc) | Bristol Myers Squibb | discontinued (2024-06, Ph1 terminated: business objectives changed) |
No recent activity
Programs whose trials ended or went quiet without an announced decision. Their status is unknown, not necessarily stopped.
| Drug | Targets | Sponsor | Status |
|---|---|---|---|
| SAIL66 | CLDN6 × CD3 × CD137 (4-1BB) | Chugai Pharmaceutical | unknown (Phase 1 completed 2026-03) |
| clesitamig | DLL3 × CD3 × CD137 (4-1BB) | Roche / Chugai | unknown (Phase 1 completed 2025-03) |
| AMG 305 | CDH3 × mesothelin × CD3 | Amgen | unknown (Phase 1 completed 2026-02) |
| DF1001 | HER2 × NKG2D × CD16a (via Fc) | Dragonfly Therapeutics | unknown (Phase 1/2 completed; CT.gov last update 2026-03) |
| DF9001 | EGFR × NKG2D × CD16a (via Fc) | Dragonfly Therapeutics | unknown (Phase 1/1b completed; CT.gov last update 2025-10) |
How this list was built
Programs were identified from company releases, SEC filings, ClinicalTrials.gov and published papers, and each has at least one primary source. A molecule counts as trispecific when it binds three different target proteins. An arm that binds albumin only to extend half-life is not counted as a target, and molecules that bind one protein twice are left out. Molecules that only review articles call trispecific, and NK-cell engagers whose third target is bound through the antibody tail (Fc), are kept but labelled. Trials are linked to a program only when a trial intervention carries the program's own name or code. Programs registered only in China's own trial registry, and very early programs, may be missing.
Frequently asked
Common questions about the Trispecific antibodies landscape
- What drugs are in the Trispecific antibodies class?
- 32 active programs in the Trispecific antibodies class are tracked in this platform view (41 listed in all, with those that have no recent activity shown separately), including ramantamig, tilrekimig, and GSK5926371. The heatmap maps every drug against the indications it is being developed for.
- What conditions are Trispecific antibodies being developed for?
- Trispecific antibodies are in clinical development across 62 indications, including Multiple Myeloma, Non-Hodgkin Lymphoma, Systemic Lupus Erythematosus, Atopic Dermatitis, and Rheumatoid Arthritis.
- How many Trispecific antibodies are in late-stage trials?
- Of the 32 tracked assets in the Trispecific antibodies class, 3 are at Phase 3 or later, developed by 27 sponsors, across 74 mapped trials.
- What are the upcoming Trispecific antibodies catalysts?
- Near-term catalysts in this class include ompekimig (data readout, Oct '26); QLS4131 (data readout, Dec '26); HC010 (data readout, Dec '26). Dates combine estimated trial readouts and confirmed FDA decision dates.
- How is the Trispecific antibodies platform compiled?
- Programs were identified from company releases, SEC filings, ClinicalTrials.gov and published papers, and each has at least one primary source. A molecule counts as trispecific when it binds three different target proteins. An arm that binds albumin only to extend half-life is not counted as a target, and molecules that bind one protein twice are left out. Molecules that only review articles call trispecific, and NK-cell engagers whose third target is bound through the antibody tail (Fc), are kept but labelled. Trials are linked to a program only when a trial intervention carries the program's own name or code. Programs registered only in China's own trial registry, and very early programs, may be missing. Each cell links to the underlying trial records.
- Is the Trispecific antibodies heatmap free to use?
- Yes — viewing and searching the Trispecific antibodies heatmap is free. A TheraRadar Pro subscription adds advanced filters, row/column selection, and one-click export to PowerPoint, PDF, and CSV.
Data: ClinicalTrials.gov · Curated program roster · Trials registered 2008 onwards.